The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn't look like much ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...